The short‐term prognosis of patients with chronic hepatitis C and mild disease is excellent. Monitoring of the progression of fibrosis is easy to perform with non‐invasive tests. Current all‐oral interferon (IFN)‐ and ribavirin (RBV)‐free regimens offer sustained viral response (SVR) rates of more than 90% as well as 12‐weeks of treatment for most patients with mild disease. Several DAA combinations can be selected to optimize efficacy and safety outcomes. A short treatment duration of 8 weeks could be indicated in most patients with mild disease. However, additional data from clinical trials and real‐life experience are needed to confirm this option. Moreover, current regimens are not cost‐effective for patients with mild disease. In practice, deferral of HCV treatment for a few years and monitoring the progression of fibrosis is a safe option until cheaper, shorter, more effective and more convenient HCV regimens become available.